Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06794541 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
A Phase 2 study of Complicated Intra-abdominal Infections (cIAI), sponsored by Tetraphase Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 5
- Study locations
NCT06794541 is a Phase 2 study of Complicated Intra-abdominal Infections (cIAI) that is actively recruiting participants, run by Tetraphase Pharmaceuticals. The registered enrollment target is 35 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT06794541, a Phase 2 study of Complicated Intra-abdominal Infections (cIAI), is actively recruiting participants, sponsored by Tetraphase Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in pediatric patients aged 8 to \<18 years with cIAI.
Conditions Studied
Interventions
- DRUG Eravacycline 2mg/kg
- DRUG Eravacycline 1.5mg/kg
Study Locations (5)
California
- UCLA Ronald Reagan University of California Los Angeles Medical Center - Los Angeles
- Children's Hospital of Orange County - Orange
Illinois
- Ann and Robert H Lurie Children's Hospital of Chicago - Chicago
Louisiana
- Children's Hospital of LSU Health Sciences Center Shreveport - Shreveport
West Virginia
- West Virginia University Medicine Children's Hospital - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-05-22 |
| Est. Completion | 2029-03-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06794541
The ClinicalTrials.gov registry entry for NCT06794541 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tetraphase Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Complicated Intra-abdominal Infections (cIAI) appearing as the primary indexed condition, and to 2 interventions - of which Eravacycline 2mg/kg is the first listed.
NCT06794541 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Illinois, Louisiana.
Frequently Asked Questions
What is clinical trial NCT06794541 about?
NCT06794541 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)". A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in pediatric patients aged 8 to \<18 years with cIAI.
What is the current status of trial NCT06794541?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2025-05-22. Estimated completion is 2029-03-19.
What conditions does trial NCT06794541 study?
This clinical trial studies the following conditions: Complicated Intra-abdominal Infections (cIAI).
What interventions are being tested in trial NCT06794541?
The interventions under investigation include: Eravacycline 2mg/kg (DRUG), Eravacycline 1.5mg/kg (DRUG).
Who is sponsoring clinical trial NCT06794541?
This trial is sponsored by Tetraphase Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06794541 being conducted?
This trial has 5 study locations across California, Illinois, Louisiana, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.